Source comparison
TB-500 Research Cycle Planning: Dosing Comparison
Acute soft tissue injury 2–3mg 4–6 weeks 1x weekly Measurable repair markers by week 3–4 Standard protocol for muscle, skin, minor ligament studies Tendon/ligament repair 3–5mg 6–8 weeks 1–2x weekly Collagen remodelling visible by week 5–6 Requires longer obse
This comparison does not assign a generated winner or score.
- Acute soft tissue injury
- 2–3mg
- 4–6 weeks
- 1x weekly
- Measurable repair markers by week 3–4
- Standard protocol for muscle, skin, minor ligament studies
- Tendon/ligament repair
- 3–5mg
- 6–8 weeks
- 1–2x weekly
- Collagen remodelling visible by week 5–6
- Requires longer observation. Collagen turnover is slow-phase
- Chronic inflammation study
- 2mg
- 8–12 weeks
- Anti-inflammatory markers by week 4–6
- Lower doses sustained over time; effects cumulative
- Wound healing (surgical)
- 2.5–3mg
- 4 weeks
- 2x weekly
- Epithelialisation acceleration by week 2–3
- Front-loaded dosing in first 14 days often used
- Cardioprotection research
- 5mg loading, 2mg maintenance
- 6 weeks (loading 1 week)
- 1x weekly after load
- Myocardial marker improvement by week 4
- Research-stage only. Not clinically validated